SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFM14A - Definitive proxy statement relating to merger or acquisition:
SEC Accession No. 0001140361-22-040942
Filing Date
2022-11-10
Accepted
2022-11-10 16:19:26
Documents
7

Document Format Files

Seq Description Document Type Size
1 DEFM14A ny20005542x1_defm14a.htm DEFM14A 3895269
2 ny20005542x1_equilliumlogo.jpg GRAPHIC 16111
3 ny20005542x1_equilliumlx1.jpg GRAPHIC 26483
4 ny20005542x1_metacrinelogo.jpg GRAPHIC 19697
5 ny20005542x1_metacrinelx1.jpg GRAPHIC 33534
6 ny20005542x1_pc01.jpg GRAPHIC 575114
7 ny20005542x1_pc02.jpg GRAPHIC 426069
  Complete submission text file 0001140361-22-040942.txt   5405848
Mailing Address 4225 EXECUTIVE SQUARE SUITE 600 SAN DIEGO CA 92037
Business Address 4225 EXECUTIVE SQUARE SUITE 600 SAN DIEGO CA 92037 858-369-7800
Metacrine, Inc. (Filer) CIK: 0001634379 (see all company filings)

IRS No.: 472297384 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFM14A | Act: 34 | File No.: 001-39512 | Film No.: 221377528
SIC: 2834 Pharmaceutical Preparations